Lyvgen Biopharma develops cross-linking dependent monoclonal antibodies and next-generation multi-antibody platforms to enhance tumor immunotherapy by activating immune responses against cancer cells. Their technology specifically targets the tumor microenvironment, improving the precision and safety of treatments while promoting the proliferation and function of anti-tumor immune cells.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICFounders
Product
Problem
Solid tumors often evade immune detection due to immunosuppressive mechanisms within the tumor microenvironment (TME). Traditional immunotherapies may lack the specificity to effectively target the TME, leading to systemic toxicity and limited efficacy.
Solution
Lyvgen Biopharma is developing a suite of antibody-based therapeutics designed to enhance anti-tumor immunity by selectively targeting and modulating the tumor microenvironment. Their cross-linking dependent monoclonal antibodies and multi-antibody platforms aim to improve the precision and safety of cancer immunotherapy. By focusing on activating immune responses specifically within the TME, Lyvgen's approach seeks to promote the proliferation and function of anti-tumor immune cells while minimizing off-target effects. The xLinkMAb platform leverages FcγRIIB cross-linking to activate TNFRSF family targets. The TROY-Ig platform creates multi-specific antibodies, including CD3 T cell engagers with CD137 co-stimulation.
Target Audience
The primary target audience includes patients with solid tumors who are not responding to existing immunotherapies, as well as clinical investigators seeking novel approaches to enhance anti-tumor immunity.
Features
- xLinkMAb platform for generating cross-linking dependent monoclonal antibodies that target TNFRSF family members.
- TROY-Ig platform for developing multi-specific antibodies, including T cell engagers, with enhanced co-stimulatory signaling.
- LVGN6051: A next-generation CD137 (4-1BB) agonistic monoclonal antibody engineered for FcγRIIB-dependent crosslinking.
- LVGN7409: A next-generation CD40 agonistic monoclonal antibody designed to promote tumor antigen presentation and T cell activation.
- LVGN3616: A PD-1 blocking monoclonal antibody for combination therapy with Lyvgen's agonistic antibodies.